These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
455 related articles for article (PubMed ID: 25885470)
1. Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib. Yamada T; Abei M; Danjoh I; Shirota R; Yamashita T; Hyodo I; Nakamura Y BMC Cancer; 2015 Apr; 15():260. PubMed ID: 25885470 [TBL] [Abstract][Full Text] [Related]
2. A robust culture method for maintaining tumorigenic cancer stem cells in the hepatocellular carcinoma cell line Li-7. Sato Y; Yamada T; Hiroyama T; Sudo K; Hasegawa N; Hyodo I; Nakamura Y Cancer Sci; 2019 May; 110(5):1644-1652. PubMed ID: 30784169 [TBL] [Abstract][Full Text] [Related]
3. A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma. Yamashita M; Wada H; Eguchi H; Ogawa H; Yamada D; Noda T; Asaoka T; Kawamoto K; Gotoh K; Umeshita K; Doki Y; Mori M Int J Oncol; 2016 Jul; 49(1):89-98. PubMed ID: 27121124 [TBL] [Abstract][Full Text] [Related]
4. Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells. Nakayama M; Ogasawara S; Akiba J; Ueda K; Koura K; Todoroki K; Kinoshita H; Yano H J Gastroenterol Hepatol; 2014 May; 29(5):1092-101. PubMed ID: 24325739 [TBL] [Abstract][Full Text] [Related]
5. The miR-200b-ZEB1 circuit regulates diverse stemness of human hepatocellular carcinoma. Tsai SC; Lin CC; Shih TC; Tseng RJ; Yu MC; Lin YJ; Hsieh SY Mol Carcinog; 2017 Sep; 56(9):2035-2047. PubMed ID: 28383782 [TBL] [Abstract][Full Text] [Related]
6. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma. Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240 [TBL] [Abstract][Full Text] [Related]
7. Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma. Kim BH; Park JW; Kim JS; Lee SK; Hong EK Gut Liver; 2019 May; 13(3):342-348. PubMed ID: 30600675 [TBL] [Abstract][Full Text] [Related]
8. Ascorbic acid predominantly kills cancer stem cell-like cells in the hepatocellular carcinoma cell line Li-7 and is more effective at low cell density and in small spheroids. Seyama Y; Sudo K; Yamada T; Tsuchiya K; Nakamura Y Biochem Biophys Res Commun; 2024 May; 709():149816. PubMed ID: 38547607 [TBL] [Abstract][Full Text] [Related]
9. Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon. Kim HM; Haraguchi N; Ishii H; Ohkuma M; Okano M; Mimori K; Eguchi H; Yamamoto H; Nagano H; Sekimoto M; Doki Y; Mori M Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S539-48. PubMed ID: 21879266 [TBL] [Abstract][Full Text] [Related]
10. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib. Ishijima N; Kanki K; Shimizu H; Shiota G Cancer Sci; 2015 May; 106(5):567-75. PubMed ID: 25683251 [TBL] [Abstract][Full Text] [Related]
11. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1. Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877 [TBL] [Abstract][Full Text] [Related]
12. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. Botchkina IL; Rowehl RA; Rivadeneira DE; Karpeh MS; Crawford H; Dufour A; Ju J; Wang Y; Leyfman Y; Botchkina GI Cancer Genomics Proteomics; 2009; 6(1):19-29. PubMed ID: 19451087 [TBL] [Abstract][Full Text] [Related]
13. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Arao T; Ueshima K; Matsumoto K; Nagai T; Kimura H; Hagiwara S; Sakurai T; Haji S; Kanazawa A; Hidaka H; Iso Y; Kubota K; Shimada M; Utsunomiya T; Hirooka M; Hiasa Y; Toyoki Y; Hakamada K; Yasui K; Kumada T; Toyoda H; Sato S; Hisai H; Kuzuya T; Tsuchiya K; Izumi N; Arii S; Nishio K; Kudo M Hepatology; 2013 Apr; 57(4):1407-15. PubMed ID: 22890726 [TBL] [Abstract][Full Text] [Related]
14. Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence. Chen W; Xiao W; Zhang K; Yin X; Lai J; Liang L; Chen D Sci Rep; 2016 Mar; 6():22976. PubMed ID: 26964667 [TBL] [Abstract][Full Text] [Related]
15. Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma. Xu J; Liang J; Meng YM; Yan J; Yu XJ; Liu CQ; Xu L; Zhuang SM; Zheng L Clin Cancer Res; 2017 Aug; 23(15):4482-4492. PubMed ID: 28223275 [No Abstract] [Full Text] [Related]
16. Identification of cancer stem cells from hepatocellular carcinoma cell lines and their related microRNAs. Xu Y; Xie Y; Wang X; Chen X; Liu Q; Ying M; Zheng Q Oncol Rep; 2013 Nov; 30(5):2056-62. PubMed ID: 24002436 [TBL] [Abstract][Full Text] [Related]
17. Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90. Yoshida M; Yamashita T; Okada H; Oishi N; Nio K; Hayashi T; Nomura Y; Hayashi T; Asahina Y; Ohwada M; Sunagozaka H; Takatori H; Colombo F; Porretti L; Honda M; Kaneko S Sci Rep; 2017 Sep; 7(1):11292. PubMed ID: 28900199 [TBL] [Abstract][Full Text] [Related]
18. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. Chen X; Lingala S; Khoobyari S; Nolta J; Zern MA; Wu J J Hepatol; 2011 Oct; 55(4):838-45. PubMed ID: 21334406 [TBL] [Abstract][Full Text] [Related]
19. Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells. Shrestha R; Bridle KR; Cao L; Crawford DHG; Jayachandran A Curr Oncol; 2021 Jun; 28(3):2150-2172. PubMed ID: 34208001 [TBL] [Abstract][Full Text] [Related]
20. Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. Yamashita T; Honda M; Nio K; Nakamoto Y; Yamashita T; Takamura H; Tani T; Zen Y; Kaneko S Cancer Res; 2010 Jun; 70(11):4687-97. PubMed ID: 20484035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]